{"filing":{"accession_number":"0001213900-26-086639","cik":"0001734005","ticker":"APM","company_name":"Niki BioSolutions, Inc.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"ea0300774-8k_nikibio.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1734005/000121390026086639/ea0300774-8k_nikibio.htm"},"events":[{"id":26159,"run_id":23757,"accession_number":"0001213900-26-086639","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses that Niki BioSolutions received a Nasdaq deficiency letter on March 5, 2026 for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), triggering a 180-day compliance period. The August 4, 2026 letter confirms the Company has regained compliance by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days. This is a delisting-risk disclosure—the Company faced potential delisting and has now resolved the deficiency, making it material to investors' assessment of the registrant's continued listing status.","company_name":"Niki BioSolutions, Inc.","ticker":"APM","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27187,"accession_number":"0001213900-26-086639","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Niki BioSolutions received a Nasdaq deficiency letter on March 5, 2026 for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), triggering a 180-day compliance period. The August 4, 2026 letter confirms the Company has regained compliance by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days. This is a delisting-risk disclosure—the Company faced potential delisting and has now resolved the deficiency, making it material to investors' assessment of the registrant's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:10:34.870107+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27187,"accession_number":"0001213900-26-086639","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Niki BioSolutions received a Nasdaq deficiency letter on March 5, 2026 for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), triggering a 180-day compliance period. The August 4, 2026 letter confirms the Company has regained compliance by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days. This is a delisting-risk disclosure—the Company faced potential delisting and has now resolved the deficiency, making it material to investors' assessment of the registrant's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:10:34.870107+00:00","company_name":"Niki BioSolutions, Inc.","ticker":"APM","filing_date":"2026-08-07"}]}